PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7

NAR Cancer · Published 2025-10-07 · DOI 10.1093/narcan/zcaf047

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/narcan/zcaf047

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors · NAR Cancer · 2025 · Same journal
• Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer · NAR Cancer · 2025 · Same journal
• Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors · NAR Cancer · 2025 · Same journal
• Efficient gene disruption with CRISPR–Cas3 in human T cells · NAR Cancer · 2026 · Same journal
• Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment · NAR Cancer · 2025 · Same journal
• The RRM domains of PARP14 mediate replication fork degradation in BRCA2-deficient cells · NAR Cancer · 2026 · Same journal
• m6A modification in R-loop homeostasis: a potential target for cancer therapeutics · NAR Cancer · 2025 · Same journal
• A common food mutagen promotes intestinal carcinogenesis by multiple mechanisms in mouse models of Lynch syndrome · NAR Cancer · 2025 · Same journal
• Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP · NAR Cancer · 2025 · Same journal
• A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment · NAR Cancer · 2025 · Same journal